[Form 4] Healthpeak Properties, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Healthpeak Properties (DOC) – Form 4 insider activity

On 07/31/2025, President & CEO Scott M. Brinker made an open-market purchase (Code “P”) of 2,930 shares of common stock at $17.06 each. Following the trade, his direct ownership rose to 210,416 shares; no indirect or derivative holdings were reported.

The filing involves only one transaction, no 10b5-1 plan disclosure and no amendments. While insider buying can signal management’s confidence, the dollar value (≈$50k) and <≈0.04 % of the ≈539 m shares outstanding render the move modestly incremental.

Positive

• CEO participated in open-market purchase, typically interpreted as confidence in future prospects.

Negative

• The transaction size is immaterial relative to both the executive’s existing holdings and the company’s share count, limiting its signaling power.

Insights

Equity Analyst

TL;DR: Minor CEO buy; positive sentiment but immaterial to valuation.

The purchase marginally lifts Brinker's stake by ~1.4 % (2,930 ÷ 207,486 prior shares) and costs roughly $50k. Such open-market buys usually lean positive, signalling that the CEO deems the stock undervalued around $17. However, relative to Healthpeak’s $9 bn+ market cap, the trade carries negligible financial impact and is unlikely to move the stock. No options or derivative adjustments were disclosed, so dilution risk is unchanged. Overall, sentiment uptick, fundamental effect minimal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brinker Scott M

(Last) (First) (Middle)

4600 SOUTH SYRACUSE STREET

SUITE 500

(Street)

DENVER CO 80237

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HEALTHPEAK PROPERTIES, INC. [ DOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2025		P		2,930	A	$17.06	210,416	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Carol Samaan, SVP, Legal (Attorney-In-Fact)	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Healthpeak (DOC) shares did CEO Scott Brinker buy?

2,930 common shares were purchased.

What price did Brinker pay per Healthpeak share?

The shares were bought at $17.06 each.

What is Brinker's total direct ownership after the purchase?

He now directly owns 210,416 DOC shares.

Was the insider action a purchase or sale?

It was an open-market purchase (Transaction Code “P”).

Did the Form 4 include any derivative security transactions?

No, no derivative securities were reported.

On what date did the insider transaction occur?

The trade took place on 07/31/2025.